Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 9
Treatment-assignment count: 0
Stratification count: 0
Manual Review Required
HER2 / ERBB2 expression
breast cancer · Immune Checkpoint Inhibitor
HER2 / ERBB2 expression is flagged as manual review required because public trials show inclusion required evidence in 11 contexts. FDA CDx context exists.
Threshold snippets
Fragmentation view
Threshold count: 3
Common snippets: HER2-low | MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT07287917 | https://clinicaltrials.gov/study/NCT01848834 | https://clinicaltrials.gov/study/NCT07054242 | https://clinicaltrials.gov/study/NCT03515798 | https://clinicaltrials.gov/study/NCT02990845 | https://clinicaltrials.gov/study/NCT05163223 | https://clinicaltrials.gov/study/NCT03222856 | https://clinicaltrials.gov/study/NCT07486687 | https://clinicaltrials.gov/study/NCT07003009 | https://clinicaltrials.gov/study/NCT04787042 | https://clinicaltrials.gov/study/NCT03492918